Session Details

F018 Side Effects May Include: Illustrative Cases of Dermatologic Adverse Events

Fri, Mar 7, 1:00 PM - 3:00 PM
W208A
2 CME Available Forum ARS CCP
View Map Launch ARS

DESCRIPTION

Open admission to eligible categories, no tuition or ticket

Dermatologists are frequently called upon to diagnose and manage patients with suspected drug rashes. With the pace of new medication development, it is important but difficult to keep up with the spectrum of side effects relevant to dermatology. This case-based interactive session will explore dermatologic adverse events. This will include cutaneous adverse reactions of non-dermatologic medications, as well as rare potential side effects of medications commonly prescribed by dermatologists. Cases will be selected that illustrate the clinical presentation, differential diagnosis, workup, and management of a variety of cutaneous adverse reactions and dermatologic drug side effects.

LEARNING OBJECTIVES

1.

Recognize different forms of cutaneous adverse reactions and uncommon side effects of dermatologic medications.

2.

Manage patients with dermatologic adverse reactions and develop evaluation and treatment plans based on reaction type.

3.

Determine the most likely causative medications for specific cutaneous adverse reactions.

SPEAKERS

Daniel Charles Butler, MD, FAAD

Daniel Charles Butler, MD, FAAD

Margaret (Molly) Moye, MD, FAAD

Margaret (Molly) Moye, MD, FAAD

Caroline Nelson, MD, FAAD

Caroline Nelson, MD, FAAD

Robert J. Smith, MD, FAAD

Robert J. Smith, MD, FAAD

SPEAKER DISCLOSURES

Daniel Charles Butler, MD, FAAD

AbbVie – Investigator(Grants/Research Funding); Galderma – Advisory Board(Fees); Leo Pharma Inc – Advisory Board(Fees); Novartis – Advisory Board(Honoraria); Pfizer Inc. – Investigator(Grants/Research Funding); Regeneron – Speaker(Honoraria);

Margaret (Molly) Moye, MD, FAAD

Forefront Dermatology – Employee (w-2 relationship)(Salary), Stockholder(Stock);

Caroline Nelson, MD, FAAD

Boehringer Ingelheim – Advisory Board(Honoraria), Investigator(Grants/Research Funding);

Robert J. Smith, MD, FAAD

No financial relationships exist with ineligible companies.